Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Myeloproliferative Disorders × edoxaban × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 5 Venous Thrombosis 4 Venous Thromboembolism 2 Pulmonary Embolism 2 Thrombosis 1 Thromboembolism 1 Myeloproliferative Disorders 1

Interventions

fludarabine phosphate 50 Cyclophosphamide 47 Peripheral Blood Stem Cell Transplantation 39 Mycophenolic Acid 32 Busulfan 31 Whole-Body Irradiation 28 Tacrolimus 27 Cyclosporine 27 Antilymphocyte Serum 27 Filgrastim 24 Methotrexate 19 Cytarabine 18 fludarabine 16 Etoposide 16 Radiotherapy 15 Melphalan 15 Methylprednisolone 12 ruxolitinib 11 thymoglobulin 8 Sirolimus 8 Psychiatric Rehabilitation 8 Flow Cytometry 8 Cyclosporins 8 Alemtuzumab 8 Granulocyte Colony-Stimulating Factor 7 Decitabine 7 Cord Blood Stem Cell Transplantation 7 Azacitidine 7 Daunorubicin 6 sargramostim 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04192916 2021-02-21

MPN-DOACs

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡